Medpace Forecast, price target & analysts
Medpace Target price 2026 - Analyst rating & recommendation
Medpace Classifications & Recommendation
Medpace Price Target
| Target Price | $612.00 |
| Price | $618.88 |
| Deviation |
1.11%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Medpace 2027 .
The average Medpace target price is $612.00.
This is
1.11%
register free of charge
$726.60
17.41%
register free of charge
$381.59
38.34%
register free of charge
|
|
| A rating was issued by 20 analysts: 7 Analysts recommend Medpace to buy, 12 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medpace stock has an average upside potential 2027 of
1.11%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.53 | 2.91 |
| 19.97% | 14.89% | |
| EBITDA Margin | 22.25% | 22.03% |
| 1.43% | 1.00% | |
| Net Margin | 17.83% | 17.19% |
| 7.00% | 3.59% |
16 Analysts have issued a sales forecast Medpace 2026 . The average Medpace sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Medpace EBITDA forecast 2026. The average Medpace EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Medpace Analysts have issued a net profit forecast 2026. The average Medpace net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 15.28 | 17.95 |
| 20.98% | 17.47% | |
| P/E | 34.48 | |
| EV/Sales | 5.77 |
16 Analysts have issued a Medpace forecast for earnings per share. The average Medpace EPS is
This results in the following potential growth metrics and future valuations:
Current Medpace Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jul 13 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
